

Eric Toussiro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5376449/publications.pdf>

Version: 2024-02-01

89
papers

3,001
citations

159585

30
h-index

168389

53
g-index

95
all docs

95
docs citations

95
times ranked

3901
citing authors

#	ARTICLE	IF	CITATIONS
1	Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. <i>Rheumatology</i> , 2009, 48, 883-886.	1.9	238
2	Epstein-Barr virus in autoimmune diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2008, 22, 883-896.	3.3	222
3	Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. <i>Rheumatology</i> , 2016, 55, 291-300.	1.9	170
4	The IL23/Th17 Pathway as a Therapeutic Target in Chronic Inflammatory Diseases. <i>Inflammation and Allergy: Drug Targets</i> , 2012, 11, 159-168.	1.8	159
5	The Contribution of Adipose Tissue and Adipokines to Inflammation in Joint Diseases. <i>Current Medicinal Chemistry</i> , 2007, 14, 1095-1100.	2.4	151
6	Paradoxical reactions under TNF- β blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. <i>RMD Open</i> , 2016, 2, e000239.	3.8	142
7	Adipose tissue, serum adipokines, and ghrelin in patients with ankylosing spondylitis. <i>Metabolism: Clinical and Experimental</i> , 2007, 56, 1383-1389.	3.4	105
8	Development of inflammatory bowel disease during anti-TNF- β therapy for inflammatory rheumatic disease. A nationwide series. <i>Joint Bone Spine</i> , 2012, 79, 457-463.	1.6	104
9	The use of TNF- β blocking agents in rheumatoid arthritis: an overview. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 581-594.	1.8	101
10	Pathophysiological links between rheumatoid arthritis and the Epstein-Barr virus: An update. <i>Joint Bone Spine</i> , 2007, 74, 418-426.	1.6	83
11	Pulmonary Nodulosis and Aseptic Granulomatous Lung Disease Occurring in Patients with Rheumatoid Arthritis Receiving Tumor Necrosis Factor- β -Blocking Agent: A Case Series. <i>Journal of Rheumatology</i> , 2009, 36, 2421-2427.	2.0	69
12	The use of TNF- β blocking agents in rheumatoid arthritis: an update. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2089-2107.	1.8	65
13	Relationships between Adipose Tissue and Psoriasis, with or without Arthritis. <i>Frontiers in Immunology</i> , 2014, 5, 368.	4.8	63
14	Increased IL-22- and IL-17A-Producing Mucosal-Associated Invariant T Cells in the Peripheral Blood of Patients With Ankylosing Spondylitis. <i>Frontiers in Immunology</i> , 2018, 9, 1610.	4.8	59
15	Vaccination and Induction of Autoimmune Diseases. <i>Inflammation and Allergy: Drug Targets</i> , 2016, 14, 94-98.	1.8	57
16	Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 1153-1159.	1.2	56
17	Imbalance between HAT and HDAC Activities in the PBMCs of Patients with Ankylosing Spondylitis or Rheumatoid Arthritis and Influence of HDAC Inhibitors on TNF Alpha Production. <i>PLoS ONE</i> , 2013, 8, e70939.	2.5	55
18	TNF- β blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: a 2-year prospective study. <i>European Journal of Nutrition</i> , 2014, 53, 951-961.	3.9	55

#	ARTICLE	IF	CITATIONS
19	Current Guidelines for the Drug Treatment of Ankylosing Spondylitis. <i>Drugs</i> , 1998, 56, 225-240.	10.9	48
20	Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity. <i>Arthritis Research and Therapy</i> , 2009, 11, R101.	3.5	46
21	Serum adipokines and adipose tissue distribution in rheumatoid arthritis and ankylosing spondylitis. A comparative study. <i>Frontiers in Immunology</i> , 2013, 4, 453.	4.8	46
22	Antiinflammatory treatment with bisphosphonates in ankylosing spondylitis. <i>Current Opinion in Rheumatology</i> , 2007, 19, 340-345.	4.3	45
23	Late-Onset Ankylosing Spondylitis and Related Spondylarthropathies. <i>Drugs and Aging</i> , 2005, 22, 451-469.	2.7	40
24	Elevated Adiponectin Serum Levels in Women with Systemic Autoimmune Diseases. <i>Mediators of Inflammation</i> , 2010, 2010, 1-6.	3.0	39
25	The role of leptin in the pathophysiology of rheumatoid arthritis. <i>Life Sciences</i> , 2015, 140, 29-36.	4.3	37
26	Dysregulated Serum IL-23 and SIRT1 Activity in Peripheral Blood Mononuclear Cells of Patients with Rheumatoid Arthritis. <i>PLoS ONE</i> , 2015, 10, e0119981.	2.5	37
27	Association of rheumatoid arthritis with multiple sclerosis: report of 14 cases and discussion of its significance. <i>Journal of Rheumatology</i> , 2006, 33, 1027-8.	2.0	34
28	Late-Onset Ankylosing Spondylitis and Spondylarthritis. <i>Drugs and Aging</i> , 2010, 27, 523-531.	2.7	32
29	Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients. <i>Autoimmunity Reviews</i> , 2017, 16, 903-910.	5.8	32
30	Anti-TNF- α therapy in ankylosing spondylitis. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 1497-1507.	1.8	31
31	Infectious Complications with Anti-TNF- α Therapy in Rheumatic Diseases: A Review. <i>Recent Patents on Inflammation and Allergy Drug Discovery</i> , 2007, 1, 39-47.	3.6	31
32	Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study. <i>Arthritis Research and Therapy</i> , 2020, 22, 224.	3.5	30
33	Ixekizumab: an anti-IL-17A monoclonal antibody for the treatment of psoriatic arthritis. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 101-107.	3.1	27
34	Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: Observational study of 30 cases in everyday practice. <i>Joint Bone Spine</i> , 2010, 77, 142-145.	1.6	26
35	Biological treatments given in patients with rheumatoid arthritis or ankylosing spondylitis modify HAT/HDAC (histone acetyltransferase/histone deacetylase) balance. <i>Joint Bone Spine</i> , 2014, 81, 544-545.	1.6	26
36	Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvement. <i>Patient Preference and Adherence</i> , 2013, 7, 369.	1.8	23

#	ARTICLE	IF	CITATIONS
37	Diagnosis and Management of Late-Onset Spondyloarthritis: Implications of Treat-to-Target Recommendations. <i>Drugs and Aging</i> , 2015, 32, 515-524.	2.7	22
38	The Risk of Progressive Multifocal Leukoencephalopathy Under Biological Agents Used in the Treatment of Chronic Inflammatory Diseases. <i>Inflammation and Allergy: Drug Targets</i> , 2014, 13, 121-127.	1.8	22
39	Predictive Factors for Disability as Evaluated by the Health Assessment Questionnaire in Rheumatoid Arthritis: A Literature Review. <i>Inflammation and Allergy: Drug Targets</i> , 2010, 9, 51-59.	1.8	21
40	Rapid and Sustained Response to Tocilizumab in Patients with Polymyalgia Rheumatica Resistant or Intolerant to Glucocorticoids: A Multicenter Open-label Study. <i>Journal of Rheumatology</i> , 2016, 43, 249-251.	2.0	21
41	MAIT cells: potent major cellular players in the IL-17 pathway of spondyloarthritis?. <i>RMD Open</i> , 2018, 4, e000821.	3.8	19
42	Could Sodium Chloride be an Environmental Trigger for Immune-Mediated Diseases? An Overview of the Experimental and Clinical Evidence. <i>Frontiers in Physiology</i> , 2018, 9, 440.	2.8	19
43	Mini-Review: The Contribution of Adipokines to Joint Inflammation in Inflammatory Rheumatic Diseases. <i>Frontiers in Endocrinology</i> , 2020, 11, 606560.	3.5	18
44	New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies. <i>Experimental Hematology and Oncology</i> , 2015, 5, 7.	5.0	17
45	Serum adipokines, adipose tissue measurements and metabolic parameters in patients with advanced radiographic knee osteoarthritis. <i>Clinical Rheumatology</i> , 2017, 36, 2531-2539.	2.2	16
46	Effects of TNF α inhibitors on adiposity and other cardiovascular risk factors: implications for the cardiovascular prognosis in patients with rheumatoid arthritis. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 525-532.	2.4	15
47	Visceral adiposity in patients with psoriatic arthritis and psoriasis alone and its relationship with metabolic and cardiovascular risk. <i>Rheumatology</i> , 2021, 60, 2816-2825.	1.9	15
48	Biologics in spondyloarthritis: TNF α inhibitors and other agents. <i>Immunotherapy</i> , 2015, 7, 669-681.	2.0	14
49	The Risk of Cardiovascular Diseases in Axial Spondyloarthritis. Current Insights. <i>Frontiers in Medicine</i> , 2021, 8, 782150.	2.6	13
50	Lymphoma complicating rheumatoid arthritis: results from a French caseâ€“control study. <i>RMD Open</i> , 2021, 7, e001698.	3.8	13
51	Sirt1 activity in peripheral blood mononuclear cells from patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2014, 81, 462-463.	1.6	11
52	Histone deacetylase inhibitors: New treatment options for inflammatory joint disease?. <i>Joint Bone Spine</i> , 2010, 77, 395-398.	1.6	10
53	Comments on the article by Tabache F. et al. â€œAcute polyarthritis after influenza A H1N1 immunizationâ€“, <i>Joint Bone Spine</i> , 2011, doi:10.1016/j.jbs.2011.02.007: Primary Sjögren's syndrome occurring after influenza A H1N1 vaccine administration. <i>Joint Bone Spine</i> , 2012, 79, 107.	1.6	10
54	Occurrence of Psoriatic Arthritis during Interferon Beta 1a Treatment for Multiple Sclerosis. <i>Case Reports in Rheumatology</i> , 2014, 2014, 1-3.	0.6	10

#	ARTICLE	IF	CITATIONS
55	The Interrelations between Biological and Targeted Synthetic Agents Used in Inflammatory Joint Diseases, and Obesity or Body Composition. <i>Metabolites</i> , 2020, 10, 107.	2.9	10
56	The Use of Janus Kinase Inhibitors in Axial Spondyloarthritis: Current Insights. <i>Pharmaceuticals</i> , 2022, 15, 270.	3.8	10
57	Interleukin-6: a promising target for the treatment of polymyalgia rheumatica or giant cell arteritis?. <i>RMD Open</i> , 2016, 2, e000305.	3.8	9
58	Unilateral Accessory Sacroiliac Joint with Bone Marrow Edema Mimicking Sacroiliitis. <i>Journal of Rheumatology</i> , 2018, 45, 1327-1328.	2.0	9
59	Pharmacological management of axial spondyloarthritis in adults. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1483-1491.	1.8	9
60	Paradoxical elevation of serum TRACP5b levels despite increase in lumbar spine bone mineral density during anti-TNF γ therapy in patients with inflammatory rheumatic disease: a 2-year prospective assessment of bone mass, bone metabolism, and the trabecular bone score. <i>European Journal of Rheumatology</i> , 2017, 4, 189-193.	0.6	9
61	New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 275-282.	1.8	8
62	Current therapeutics for spondyloarthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2469-2477.	1.8	7
63	Abatacept as Adjunctive Therapy in Refractory Polymyalgia Rheumatica. <i>Journal of Rheumatology</i> , 2021, 48, 1888-1889.	2.0	7
64	Sirt-1 activity in PBMC from patients with spondyloarthritis. <i>Joint Bone Spine</i> , 2015, 82, 210-211.	1.6	6
65	Dysphagia Related to Esophagus Compression by Anterior Cervical Ossification in a Patient with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2015, 42, 1922-1923.	2.0	6
66	Rituximab for rheumatoid arthritis-associated large granular lymphocytic leukemia, a retrospective case series. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1109-1113.	3.4	6
67	Bacillus calmette-guérin vaccination in a patient treated with infliximab. <i>Journal of Rheumatology</i> , 2005, 32, 2500-1.	2.0	6
68	Short-Term Efficacy of Hyaluronic Acid Joint Injections in a Case of Ochronotic Arthropathy. <i>Journal of Clinical Rheumatology</i> , 2013, 19, 152-153.	0.9	4
69	Rhabdomyolysis Occurring under Statins after Intense Physical Activity in a Marathon Runner. <i>Case Reports in Rheumatology</i> , 2015, 2015, 1-2.	0.6	4
70	Multiple paradoxical adverse events in a patient with ankylosing spondylitis treated with adalimumab. <i>European Journal of Dermatology</i> , 2016, 26, 406-408.	0.6	4
71	The alternative CD20 transcript variant is not a surrogate marker for resistance to rituximab in patients with rheumatoid arthritis: Fig. 1. <i>Rheumatology</i> , 2015, 54, 1744-1745.	1.9	3
72	Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trials. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 2087-2094.	4.3	3

#	ARTICLE	IF	CITATIONS
73	Effects of TNF- α Inhibitors on Abdominal Adiposity in Patients with Inflammatory Rheumatic Diseases. Journal of Rheumatology, 2014, 41, 2491-2491.	2.0	2
74	Relations physiopathologiques polyarthrite rhumatoïde et virus d'Epstein-Barr: État des lieux. Revue Du Rhumatisme (Edition Francaise), 2007, 74, 814-823.	0.0	1
75	Tocilizumab failure in malignancy-related polymyalgia rheumatica. Joint Bone Spine, 2020, 87, 366-368.	1.6	1
76	L5 Radiculopathy with Neurological Deficit Due To Sacral Insufficiency Fracture. Journal of Rheumatology, 2020, 47, 939-940.	2.0	1
77	Management of ankylosing spondylitis with infliximab. Open Access Rheumatology: Research and Reviews, 2009, 1, 69-82.	1.6	1
78	Lack of association between the TNFAIP3 rs2230926 variant and rheumatoid arthritis-associated lymphoma. Joint Bone Spine, 2022, 89, 105390.	1.6	1
79	Correspondence to the article by Park Min-Chan «Pro-inflammatory effect of leptin on peripheral blood mononuclear cells of patients with ankylosing spondylitis» Joint Bone Spine 2009;76:170-175. Joint Bone Spine, 2010, 77, 90.	1.6	0
80	Correspondance concernant l'article de Min-Chan Park «Effet pro-inflammatoire de la leptine sur les cellules mononucléées de sang de patients atteints de spondylarthrite ankylosante». Revue Du Rhumatisme (Edition Francaise), 2010, 77, 113-114.	0.0	0
81	Développement d'un syndrome de Gougerot-Sjögren primitif après administration de vaccin antigrippal A/H1N1. Commentaire de l'article de F. Tabache et al. «Polyarthrite aiguë après vaccination antigrippale A/H1N1», Joint Bone Spine, 2011, doi:10.1016/j.jbs.2011.02.007. Revue Du Rhumatisme (Edition Francaise), 2012, 79, 181-182.	0.0	0
82	Développement de maladies inflammatoires intestinales au cours de traitement anti-TNF- α dans les rhumatismes inflammatoires. Étude nationale. Revue Du Rhumatisme (Edition Francaise), 2012, 79, 323-329.	0.0	0
83	Acute Pancreatitis Occurring after Pamidronate Infusions in Two Patients with Spondyloarthritis. Case Reports in Rheumatology, 2013, 2013, 1-3.	0.6	0
84	Sarcoidosis induced by TNF α antagonists. Comments about the article by Vigne et al. (Joint Bone Spine) Tj ETQq0 0.0 rgBT /Qverlock 10	1.6	0
85	SAT0167...INCREASED HIGH MOLECULAR WEIGHT ADIPONECTIN AND LEAN MASS DURING TOCILIZUMAB TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS. A 12 MONTH MULTICENTER STUDY. , 2019, , .		0
86	An unusual association of CANOMAD and rheumatoid arthritis with a long-term follow-up. Joint Bone Spine, 2020, 87, 263-264.	1.6	0
87	Résistance au tocilizumab de pseudo-polyarthrites rhizoméliques associées à une néoplasie: 2 cas. Revue Du Rhumatisme (Edition Francaise), 2020, 87, 417-418.	0.0	0
88	Lymphoma complicating rheumatoid arthritis: results from a French case-control study. RMD Open, 2021, 7, .	3.8	0
89	Characterization of mucosal-associated invariant T cells in blood of patients with axial spondyloarthritis and in axial entheses of healthy controls: comment on the article by Rosine et al. Arthritis and Rheumatology, 2022, 74, 2045-2046.	5.6	0